🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "major milestone" in the battle against drug-resistant strains of the bacteria, according to researchers.

A Worldwide Public Health Issue

Cases of gonorrhoea are increasing globally, with estimates suggesting over 82 million infections each year. Especially elevated rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have reached a record high, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary advancement in the face of increasing worldwide cases, the spread of superbugs and the highly restricted therapeutic options currently available.”

Public health authorities are deeply concerned about the surge in drug-resistant strains. The WHO has designated it as a "high-priority threat". Recent surveillance found that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Secure Authorization

One new antibiotic, marketed under the name Nuzolvence, was approved by the US FDA in mid-December for treating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Experts believe that specific application of this new drug will help delay the development of resistance.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, also received approval in close succession. This treatment, which is also used to treat urinary tract infections, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin emerged from a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP collaborated with the drug firm Innoviva to develop it.

“This milestone signifies a significant shift in the management of superbug gonorrhoea, which previously has been outpacing antibiotic development.”

Research Study Results and Global Access

Based on findings released by a major medical journal, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This establishes an similar efficacy with the typical regimen, which involves an injection and a pill. The study included hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the authority to make available and distribute the drug in numerous developing nations.

Medical professionals treating patients have shared optimism. Access to a single-dose, oral treatment of this kind is seen as a "critical tool" for managing the epidemic. This is deemed essential to lessen the impact of the infection for people and to stop the proliferation of highly drug-resistant gonorrhoea around the world.